Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels | Zendy

Eugènia Negredo | Zendy; Adolfo DíezPérez | Zendy; Anna Bonjoch | Zendy; Peré Domingo | Zendy; Núria PérezÁlvarez | Zendy; Mar Gutiérrez | Zendy; Gràcia Mateo | Zendy; Jordi Puig | Zendy; Patricia Echeverría | Zendy; Roser Escrig | Zendy; Bonaventura Clotet | Zendy

Open Access

Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels

Author(s) -

Eugènia Negredo,

Adolfo DíezPérez,

Anna Bonjoch,

Peré Domingo,

Núria PérezÁlvarez,

Mar Gutiérrez,

Gràcia Mateo,

Jordi Puig,

Patricia Echeverría,

Roser Escrig,

Bonaventura Clotet

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv063

Subject(s) - sclerostin , bone remodeling , abacavir , osteoprotegerin , medicine , osteocalcin , endocrinology , bone mineral , n terminal telopeptide , bone resorption , osteopenia , osteoporosis , bone density , chemistry , receptor , immunology , alkaline phosphatase , human immunodeficiency virus (hiv) , activator (genetics) , viral load , wnt signaling pathway , biochemistry , antiretroviral therapy , gene , enzyme

Tenofovir is involved in accelerated bone mineral density (BMD) loss.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research